Dermamelan Medical Depigmentation Program
Supervised long-course depigmentation program for melasma, PIH, and stubborn acquired pigmentation
이 치료에 대해
Dermamelan is mesoestetic’s medically supervised depigmentation program for recurrent acquired pigmentation such as melasma, post-inflammatory hyperpigmentation, and sun-driven dyschromia. Rather than acting as a one-off peel, it combines an in-clinic initiation phase with several months of guided home maintenance.
It remains visible across Japan, Korea, Europe, and the US in pigment-management pathways where relapse control matters as much as initial lightening. It is closely related to the lighter cosmelan concept, but this DB entry is centered on Dermamelan because that is where the clearer peer-reviewed evidence was found.
작용 기전
The program combines an office-applied intensive mask with prolonged home therapy to regulate excess melanogenesis, accelerate turnover of pigmented epidermal cells, and reduce persistent post-inflammatory dyschromia. Its action is not limited to exfoliation; it is positioned as longer-term control of melanocyte activity and pigment production, which is why maintenance is central in relapse-prone patients.
적응증
기대 효과
In the product-specific pilot study, the Dermamelan arm showed about a 50% MASI improvement and suggested greater reduction of deeper melanin than 4% hydroquinone. In practice, initial visible changes appear over 1-4 weeks, but real assessment usually spans 3-4 months because relapse control is part of the endpoint. This is not a one-and-done treatment; adherence to photoprotection and maintenance largely determines results.
임상 근거
위험 및 부작용
Marked redness, burning, dryness, peeling, contact dermatitis, reactive PIH, and rebound recurrence can occur. It is not ideal during pregnancy, with barrier disruption, active inflammatory dermatoses, or poor sun-control adherence. If combined with lasers, irritation thresholds must be judged carefully.